Abstract mRNA-based drugs have tremendous potential as clinical treatments, however, a
major challenge in realizing this drug class will promise to develop methods for safely …

The emergency use authorizations (EUAs) of two mRNA-based severe acute respiratory
syndrome coronavirus (SARS-CoV)-2 vaccines approximately 11 months after publication of …

In the past few years, there has been increasing focus on the use of messenger RNA
(mRNA) as a new therapeutic modality. Current clinical efforts encompassing mRNA-based …

Abstract mRNA vaccines have emerged as highly effective strategies in the prophylaxis and
treatment of diseases, thanks largely although not totally to their extraordinary performance …

Over the past several decades, messenger RNA (mRNA) vaccines have progressed from a
scepticism-inducing idea to clinical reality. In 2020, the COVID-19 pandemic catalysed the …

Vaccines based on messenger RNA (mRNA) are attracting worldwide attention as the Pfizer
and Moderna vaccines have been authorized for emergency use by the US Food and Drug …

In the last two decades, there has been growing interest in mRNA-based technology for the
development of prophylactic vaccines against infectious diseases. Technological …

Abstract mRNA vaccines represent a promising alternative to conventional vaccine
approaches because of their high potency, capacity for rapid development and potential for …

mRNA vaccines have been demonstrated as a powerful alternative to traditional
conventional vaccines because of their high potency, safety and efficacy, capacity for rapid …

During the last two decades, there has been broad interest in RNA-based technologies for
the development of prophylactic and therapeutic vaccines. Preclinical and clinical trials have …